Dupixent
dupilumab
Dermatitis, Atopic
Prurigo
Esophageal Diseases
Asthma
Sinusitis
Date of authorisation:
Revision: 33
Last updated:
MedicineHumanAuthorised
Cibinqo
abrocitinib
Dermatitis, Atopic
Date of authorisation:
Revision: 8
Last updated:
MedicineHumanAuthorised
Protopic
tacrolimus
Dermatitis, Atopic
Date of authorisation:
Revision: 28
Last updated:
MedicineHumanAuthorised
Adtralza
tralokinumab
Dermatitis, Atopic
Date of authorisation:
Revision: 4
Last updated:
MedicineHumanAuthorised
Ebglyss
Lebrikizumab
Dermatitis, Atopic
Date of authorisation:
Last updated:
MedicineHumanAuthorised
EMEA-001501-PIP04-19-M02 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: P/0541/2022
Route(s) of administration: Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Janus kinase inhibitors (JAKi) - referral
tofacitinib
abrocitinib
baricitinib
upadacitinib
filgotinib
Article 20 procedures
Status: European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
EMEA-001501-PIP11-21 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Dermatology
PIP number: P/0178/2022
Route(s) of administration: Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-001900-PIP02-17-M06 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: P/0096/2022
Route(s) of administration: Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-001501-PIP09-21 - paediatric investigation plan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: P/0120/2022
Route(s) of administration: Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman